| Seely, K.A., Levi, M.A. and Prather, P.L., The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists., J. Pharmacol. Exp. Ther., 330(1):31-39, 2009. Mazur, A., Lichti, C.F., Prather, P.L., Zielinska, A.K., Bratton, S.M., Gallus-Zawada, A., Finel, M., Miller, G.P. and Radominska-Pandya, A. and Moran, J.H., Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids., Drug Metab. Disposition, 37(7):1496-1504, 2009. Shoemaker, J.L., Seely, K.A., Reed, R.L., Crow, J.P. and Prather, P.L., The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset., J. Neurochem., 101:87-98, 2007. Shoemaker, J.L., Ruckle, M.B., Mayeux, P.R. and Prather, P.L., Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors., J. Pharmacol. Exp. Ther., 315:828-838, 2005. Shoemaker, J.L., Joseph, B.K., Ruckle, M.B., Mayeux, P.R. and Prather, P.L., The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors., J. Pharmacol. Exp. Ther., 314:868-875, 2005. Liu, J.G. and Prather, P.L., Chronic agonist treatment converts antagonists into inverse agonists at δ-opioid receptors., J. Pharmacol. Exp. Ther., 303:1070-1079, 2002. |
